Last reviewed · How we verify
Melan-A VLP vaccine, IMP321 adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Melan-A VLP vaccine, IMP321 adjuvant (Melan-A VLP vaccine, IMP321 adjuvant) — Prof. Serge Leyvraz.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Melan-A VLP vaccine, IMP321 adjuvant TARGET | Melan-A VLP vaccine, IMP321 adjuvant | Prof. Serge Leyvraz | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Melan-A VLP vaccine, IMP321 adjuvant CI watch — RSS
- Melan-A VLP vaccine, IMP321 adjuvant CI watch — Atom
- Melan-A VLP vaccine, IMP321 adjuvant CI watch — JSON
- Melan-A VLP vaccine, IMP321 adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). Melan-A VLP vaccine, IMP321 adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/melan-a-vlp-vaccine-imp321-adjuvant. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab